Enterprise Value

113.7M

Cash

41.79M

Avg Qtr Burn

-8.72M

Short % of Float

3.95%

Insider Ownership

3.08%

Institutional Own.

53.32%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Uproleselan (GMI-1271) Details
Acute myeloid leukemia, Cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 2/3

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

GMI-1687 Details
Sickle cell disease

Phase 1a

Data readout

Rivipansel (GMI-1070) Details
SCD (Sickle Cell Disease)

Failed

Discontinued

GMI-1359 Details
Breast cancer

Failed

Discontinued